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Yu-Hao Zhou†, Xiao-Fei Ye†, Fei-Fei Yu, Xiao Zhang, Ying-Yi Qin, Jian Lu and Jia He*Abstract
Background: Fibrates has been extensively used to improve plasma lipid levels and prevent adverse cardiovascular
outcomes. However, the effect of fibrates on stroke is unclear at the present time. We therefore carried out a
comprehensive systematic review and meta-analysis to evaluate the effects of fibrates on stroke.
Methods: We systematically searched Medline, Embase, the Cochrane Central Register of Controlled Trials,
reference lists of articles, and proceedings of major meetings to identify studies for our analysis. We included
randomized placebo controlled trials which reported the effects of fibrates on stroke. Relative risk (RR) was used to
measure the effect of fibrates on the risk of stroke under random effect model. The analysis was further stratified by
factors that could affect the treatment effects.
Results: Overall, fibrate therapy was not associated with a significant reduction on the risk of stroke (RR, 1.02,
95% CI, 0.90 to 1.16, P = 0.78). In the subgroup analyses, we observed that gemfibrozil therapy showed a beneficial
effect on stroke (RR, 0.72, 95% CI, 0.53 to 0.98, P = 0.04). Similarly, fibrate therapy comparing to placebo had no
effect on the incidence of fatal stroke. Subgroup analysis suggested that fibrate therapy showed an effect on fatal
stroke when the Jadad score more than 3 (RR, 0.41, 95% CI, 0.17 to 1.00, P = 0.049). Furthermore, a sensitivity
analysis indicated that fibrate therapy may play a role in fatal stroke (RR, 0.49, 95% CI, 0.26 to 0.93, P = 0.03) for
patients with previous diabetes, cardiovascular disease or stroke.
Conclusions: Our study indicated that fibrate therapy might play an important role in reducing the risk of fatal
stroke in patients with previous diabetes, cardiovascular disease or stroke. However, it did not have an effect on the
incidence of stroke.
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Cardiovascular disease is the leading cause of premature
morbidity and mortality for both men and women world-
wide, accounting for 30.9% of global mortality and 10.3%
of global burden of disease [1,2]. Over the past few de-
cades, a series of studies have shown a strong correlation
between hypertriglyceridemia and cardiovascular disease.
Those studies indicated that elevated triglyceride levels as
a risk factor of coronary artery disease. In addition, it has
been suggested that raised triglycerides in the blood
should be lowered as a therapeutic approach to prevent
cardiovascular disease [3-7]. However, reduction of the* Correspondence: hejia63@yahoo.com
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reproduction in any medium, provided the orconcentrations of triglycerides in the blood has not been
shown consistently to be beneficial for stroke [8].
Recently, a meta-analysis [5] revealed that statins could
effectively achieve target cholesterol goals and reduce the
risk of stroke. However, certain patients intolerant to sta-
tins also need stroke prevention. In addition, a high re-
sidual risk of coronary and other cardiovascular events
persists during the statin therapy. It is necessary to find
additional effective preventive therapies. Fibrates has been
clearly shown to be effective in elevating HDL cholesterol,
lowering triglyceride concentrations, reducing LDL chol-
esterol and chylomicron remnants [9]. However, inconsis-
tent clinical results have been reported [8,10], and the
efficacy of fibrates lowering triglyceride levels in reducing
the risk of stroke has not been confirmed by randomized
trials.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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limited effect on the event of stroke. VA-HIT study [10]
showed that fibrates significantly reduced the risk of
stroke. In order to reveal the effect of fibrates on the
event of stroke further, data from recent trials is needed
to be re-evaluated and combined with former literatures.
Therefore, we carried out a systematic review and meta-
analysis of pooled data from randomized controlled
trials which reported stroke as the endpoint in relation
to fibrate therapy.
Methods
Data sources, search strategy, and selection criteria
Randomized, double-blind, placebo-controlled, and trials
of fibrate therapy in English-language literature were
eligible for inclusion in our research, regardless of pub-
lication status (published, unpublished, in press, or in
progress). References of our meta-analysis were identi-
fied through searches of Pubmed, EmBase, and the
Cochrane Central Register of Controlled Trials, with a
date up to Dec 10, 2011. We searched with the following
terms “clofibrate”, “bezafibrate”, “gemfibrozil”, “fenofi-
brate”, “procetofen”, and “randomised controlled trials”.
The search was restricted to trials in human beings and
published in English. References were also identified by
screening the proceedings of annual meeting, bibliog-
raphies of publications for potentially relevant trials. We
restricted our research to randomized controlled trials,
which were less likely to be subject to confounding and
bias than observational studies. Studies were eligible for
inclusion when they met the following requirements:
randomized controlled design; the intervention duration
was at least 6 months and follow-up period was more
than 12 months; recorded data on the event of stroke.
The literature search was undertaken independently by 2
authors (Fei-Fei Yu and Ying-Yi. Qin) with a standar-
dized approach, and any disagreement between these 2
authors was settled by a third author (Yu-Hao. Zhou)
until a consensus was reached. This review was conducted
and reported according to the PRISMA (Preferred Re-
porting Items for Systematic Reviews and Meta-Analysis)
Statement issued in 2009 (Additional file 1) [11].
Data collection and quality assessment
3,279 identified studies were reviewed by 2 authors
(Xiao-Fei Ye and Xiao Zhang) independently. Other two
investigators (Ying-Yi Qin and Jian Lu) independently
checked each full-text trial for eligibility and extracted
and tabulated all relevant data with a standard protocol
and reviewed by a third investigators (Yu-Hao Zhou).
Any discrepancy was settled by group discussion, and
then the primary authors (Yu-Hao. Zhou and Jia He)
made the final decision. Recorded data variables were
shown as follows: first author or study group’s name,publication year, the number of patients enrolled, gen-
der, mean age, pre-existent diseases, percentage of dia-
betes, total cholesterol, blinding, interventions, control,
the duration of follow-up, lifestyle modification, and the
event of stroke. Study quality was assessed by the Jadad
score [12].
Statistical analysis
We assessed the overall effect of fibrate therapy on the
risk of stroke based on all data from the included trials.
Outcome was reported by relative risks (RR) with 95%
confidence intervals (CIs) to evaluate the effect of fibrate
therapy on the event of stroke. We then performed
subgroup analysis by the type of drug (clofibrate, bez-
afibrate, gemfibrozil, or fenofibrate), mean age (≥60 or
<60), triglyceride lowering (≥10% or <10%), pre-exsistent
diseases (diabetes, stroke, or other), number of patients
(≥1000 or <1000), published years (after 2000 or previous),
duration of follow-up (≥60 months or <60 months), base-
line total cholesterol (≥6.0 mmol/L or <6.0 mmol/L), total
cholesterol lowering (≥5% or <5%), triglyceridemia (≥30%
or <30%), or Jadad score (score 4 or 5, less than 4). Fur-
thermore, the effect of between-group triglyceride lo-
wering, and total cholesterol change on stroke incidence
was assessed by linear regression model for the logarith-
mic relative risk of stroke. Although the fixed-effect and
random-effect models yielded similar conclusions, we
used random-effect model with Mantel-Haenszel statistics
in our study. Under this model, we assumed that the true
underlying effect varied among included trials due to the
different pre-existent diseases, intervention regimens, and
the duration of follow-up which were involved in the ori-
ginal trials. Moreover, many investigators also considered
the random-effect model to be a more natural choice than
the fixed-effect model in medical decision-making con-
texts [13,14]. Heterogeneity of treatment effects among
studies was investigated by scatter plot analysis and the
heterogeneity I2 statistic [15]. Egger’s test [16] was used to
check for potential publication bias. All P values were
reported as two-sided and P values less than 0.05 were
regarded as statistically significant for all included studies.
SAS software (version 9.1.3) was used for the regression
analysis and STATA (version 10.0) was used for the meta-
analysis.
Results
We identified 3,279 potential trials from our initial
searches and 3,191 were excluded during a preliminary
review. Among the 88 trials retrieved for detailed assess-
ment, 78 trials were excluded for lack of data on stroke,
polytherapy in either treatment group or control group,
or reporting the same population. Our final analysis
included 10 randomized controlled trials, which con-
sisted of 37,791 individual patients. Table 1 summarized





Pre-existent diseases Diabetes Total
cholesterol
(mmol/L)
BIP study [8] (2000) 3090 2825 (91%) 60 MI more than 6 month, and less than
5 year and/or stable angina
10% 5.5
VA-HIT study [10] (1999) 2531 2531 (100%) 64 Histories of CHD 25% 4.5




Study Group [18] (1973)
532 532 (100%) NR cerebral I or TIA within 12 month 24% 6.2
Coronary Drug Project Research Group
[19] (1975)
3892 3892 (100%) NR MI more than 3 month NR 6.5
WHO-COOP committee of principal
Investigators [20] (1978)
10627 10627 (100%) 46 Upper third level of cholesterol from
15 745 healthy men
0% 6.4
LEADER study [21,22] (2002) 1568 1568 (100%) 68 lower extremity arterial disease 66% 5.6
E J Whitney [23] (2005) 9795 6138 (63%) 62 Type 2 diabetes mellitus 100% 5.0
FIELD study [24] (2005) 143 132 (92%) 63 Low HDL-C and coronary disease NR 5.1
The ACCORD Study Group [25] (2010) 5518 3824 (69%) 62 Type 2 diabetes mellitus 100% 5.0
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their participants. Design characteristics of included
trials were presented in Table 2. The trials compared
fibrate therapy with placebo were included in our re-
search. Sample size of the trials ranged from 95 to 10,627,
with a mean of 3,779, and the duration of follow-up for
patients ranged from 30 to 104 months. 4 of included
trials [17-20] evaluated the effect of clofibrates, 2 trials
[8,21,22] evaluated the effect of bezafibrate, 2 studies
[10,23] evaluated the effect of gemfibrozil, and the re-
maining 2 studies [24,25] evaluated the effect of fenofi-
brate. In addition, 9 trials included patients with pre-
existing disease: 2 trials [17,18] reported that patients
had the history of cerebral or TIA, and the remaining
7 trials [8,10,19,21-25] reported patients had the history ofTable 2 Design of trials included in the systematic review and
Source Blinding Intervention
BIP study [8] (2000) Double Bezafibrate 400 mg daily
VA-HIT study [10] (1999) Double Gemfibrozil 1200 mg daily
Acheson J [17] (1972) Open Clofibrate 1–2 g daily
Veterans Administration Cooperative
Study Group [18] (1973)
Double Clofibrate 2 g daily
Coronary Drug Project Research
Group [19] (1975)
Double Clofibrate 1.8 g daily
WHO-COOP committee of principal
Investigators [20] (1978)
Double Clofibrate 1.6 g daily
LEADER study [21,22] (2002) Double Bezafibrate 400 mg daily
E J Whitney [23] (2005) Double Gemfibrozil 600 mg daily
FIELD study [24] (2005) Double Fenofibrate 200 mg daily
The ACCORD Study Group [25] (2010) Double Fenofibrate 160 mg dailymyocardial infarction, diabetes, coronary disease or lower
extremity arterial disease. Another trial [20] included par-
ticipants with high level of cholesterol. The quality of the
trials was assessed according to the pre-fixed criteria using
the Jadad score. Among the 10 included trials, five trials
[8,10,19,24,25] scored 4, one [23] scored 3, two [20,21]
scored 2, one [18] scored 1 and the remaining one trial
[17] scored 0.
After pooling included trials, we concluded that fibrate
therapy had no effect on the risk of stroke (RR, 1.02;
95% CI: 0.90 to 1.16). Heterogeneity test for all analysis
in Table 3 showed that all P value for heterogeneity were
larger than 0.05, and heterogeneity was not statistically
significant in the overall analysis and in subgroup ana-
lysis. Furthermore, sensitivity analysis also showed thatmeta-analysis




Placebo 74.4 Yes 4
Placebo 36–60 Yes 4
Corn oil then placebo 104 in treatment group
91 in placebo group
NR 0
Placebo 54 NR 1
Placebo 74.4 NR 4
Olive oil Placebo 63.6 Yes 2
Placebo 55.2 NR 2
Placebo 30 Yes 3
Placebo 60 Yes 4
Placebo 56.4 Yes 4
Table 3 Subgroup analysis for the effect of fibrates therapy on stoke, and fatal stroke
Group Stroke event/total patients Relative risk (RR) P value Heterogeneity P value for
heterogeneityFibrates Placebo
stroke Published years
after 2000 341/10062 351/10052 0.97 (0.84 to 1.13) 0.72 0% 0.51
before 2000 292/8013 471/9664 1.06 (0.84 to 1.33) 0.63 52% 0.08
Number of patients
≥1000 573/17689 775/19332 0.99 (0.87, 1.12) 0.85 23% 0.26
<1000 60/386 47/384 1.23 (0.80, 1.90) 0.34 30% 0.24
Mean age
<60 32/5331 27/5296 1.18 (0.71 to 1.96) 0.53 - -
≥60 405/11326 439/11319 0.93 (0.80 to 1.08) 0.34 17% 0.30
Gender
male 329/8749 498/10401 1.09 (0.86 to 1.38) 0.47 56% 0.06
Male/female 304/9326 324/9315 0.95 (0.82 to 1.10) 0.48 0% 0.77
Drug
clofibrate 228/6749 383/8397 1.15 (0.98 to 1.34) 0.08 0% 0.59
bezafibrate 132/2331 126/2327 1.05 (0.80 to 1.38) 0.37 21% 0.26
gemfibrozil 64/1335 90/1339 0.72 (0.53 to 0.98) 0.04 0% 0.41
fenofibrate 209/7660 223/7653 0.94 (0.78 to 1.13) 0.49 0% 0.49
Control
corn or olive oil 55/5378 49/5344 1.11 (0.80 to 1.54) 0.53 0% 0.76
placebo 572/12697 761/14372 1.02 (0.88 to 1.17) 0.83 32% 0.17
Follow-up
≥60 months 421/12924 612/14575 1.01 (0.90 to 1.14) 0.85 0% 0.62
<60 months 212/5151 210/5141 1.05 (0.76 to 1.46) 0.75 59% 0.05
Total cholesterol
≥6.0 mmol/L 228/6749 383/8397 1.15 (0.98 to 1.34) 0.08 0% 0.59
<6.0 mmol/L 405/11326 439/11319 0.93 (0.80 to 1.08) 0.34 17% 0.30
Total cholesterol lowering
≥5% 409/12230 586/13890 1.04 (0.92 to 1.18) 0.49 0% 0.51
<5% 173/3080 188/3073 0.98 (0.67 to 1.45) 0.93 71% 0.03
Triglyceride lowering
≥30% 101/1603 113/1603 0.96 (0.46 to 1.99) 0.92 74% 0.02
<30% 477/11094 660/12769 1.02 (0.91 to 1.15) 0.69 0% 0.51
Pre-exsistent diseases
stroke 60/315 45/312 1.28 (0.86 to 1.90) 0.23 35% 0.22
diabetes 209/7660 223/7653 0.94 (0.78 to 1.13) 0.49 0% 0.49
other 364/10100 554/11751 1.00 (0.83 to 1.20) 0.99 36% 0.16
Jadad score
4 481/11575 699/13251 0.95 (0.82 to 1.09) 0.48 30% 0.22
<4 152/6500 123/6465 1.22 (0.98 to 1.52) 0.07 0% 0.58
Overall 633/18075 822/19716 1.02 (0.90 to 1.16) 0.78 27% 0.20
Fatal stroke Published years
after 2000 17/3548 17/3538 0.93 (0.33 to 2.60) 0.89 51% 0.15
before 2000 24/6910 35/6875 0.70 (0.41 to 1.19) 0.18 0% 0.47
Zhou et al. BMC Neurology 2013, 13:1 Page 4 of 8
http://www.biomedcentral.com/1471-2377/13/1
Table 3 Subgroup analysis for the effect of fibrates therapy on stoke, and fatal stroke (Continued)
Number of patients
≥1000 34/10143 40/10101 0.82 (0.45 to 1.48) 0.51 32% 0.22
<1000 7/315 12/312 0.59 (0.23 to 1.47) 0.26 0% 0.59
Mean age
<60 14/5331 14/5296 0.99 (0.47 to 2.08) 0.99 - -
≥60 20/4812 26/4805 0.69 (0.27 to 1.75) 0.44 53% 0.12
Gender
male 35/7646 39/7612 0.89 (0.53 to 1.51) 0.67 19% 0.30
Male/female 6/2812 13/2801 0.46 (0.18 to 1.21) 0.12 0% 0.85
Drug
clofibrate 21/5646 26/5608 0.81 (0.45 to 1.44) 0.47 0% 0.59
bezafibrate 13/783 9/785 1.45 (0.62 to 3.37) 0.39 - -
gemfibrozil 3/1264 9/1267 0.33 (0.09 to 1.23) 0.10 - -
fenofibrate 4/2765 8/2753 0.50 (0.15 to 1.65) 0.25 - -
Control
corn or olive oil 16/5378 19/5344 0.85 (0.43 to 1.66) 0.63 0% 0.32
placebo 25/5151 33/5141 0.73 (0.38 to 1.40) 0.34 30% 0.23
Follow-up
≥60 months 16/5378 19/5344 0.85 (0.43 to 1.66) 0.63 0% 0.32
<60 months 25/5080 33/5069 0.73 (0.38 to 1.40) 0.34 30% 0.23
Total cholesterol
≥6.0 mmol/L 21/5646 26/5608 0.81 (0.45 to 1.44) 0.47 0% 0.59
<6.0 mmol/L 20/4812 26/4805 0.69 (0.27 to 1.75) 0.44 53% 0.12
Total cholesterol lowering
≥5% 29/6161 28/6129 1.04 (0.62 to 1.76) 0.87 0% 0.38
<5% 8/1532 16/1531 0.51 (0.22 to 1.20) 0.12 0% 0.40
Triglyceride lowering
≥30% 8/1532 16/1531 0.51 (0.22 to 1.20) 0.12 0% 0.40
<30% 17/3548 17/3538 0.93 (0.33 to 2.60) 0.89 51% 0.15
Pre-exsistent diseases
stroke 7/315 12/312 0.59 (0.23 to 1.47) 0.26 0% 0.59
diabetes 4/2765 8/2753 0.50 (0.15 to 1.65) 0.25 - -
other 30/7378 32/7348 0.91 (0.45 to 1.83) 0.78 42% 0.18
Jadad score
4 7/4029 17/4020 0.41 (0.17 to 1.00) 0.05 0% 0.66
<4 34/6429 35/6393 0.97 (0.60 to 1.57) 0.91 0% 0.51
Overall 41/10458 52/10413 0.79 (0.51 to 1.23) 0.30 6% 0.38
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any particular trial.
Six trials [10,17,18,20,23,25] included 20871 indivi-
duals and 93 total events of fatal stroke were recorded.
There was no evidence to support that fibrate therapy
protected against fatal stroke (RR, 0.79; 95% CI, 0.51 to
1.23, Table 3) with homogenity across included studies.
Furthermore, we observed that the results were notaffected by excluding of any specific trial from the
pooled analysis.
Post-intervention total cholesterol lowering was mea-
sured in all included studies except one [23]. There was
considerable variation in the net and relative reduction
of total cholesterol concentration among the included
trials, ranging from 3.0% to 19.6% (Table 4). We observed
an inverse relation between total cholesterol lowering and







and 95% CI for stroke
Relative risk (RR)
and 95% CI for fatal stroke
BIP study [8] (2000) 11.0% 3.0% 0.93 (0.68, 1.27) -
VA-HIT study [10] (1999) 31.0% 4.0% 0.73 (0.53, 1.00) 0.33 (0.09, 1.23)
Acheson J [17] (1972) NR 6.4% 1.07 (0.70, 1.63) 0.41 (0.08, 2.00)
Veterans Administration Cooperative
Study Group [18] (1973)
33.2% 3.7% 1.58 (0.97, 2.59) 0.70 (0.23, 2.19)
Coronary Drug Project Research Group
[19] (1975)
22.3% 6.5% 1.11 (0.92, 1.34) -
WHO-COOP committee of principal
Investigators [20] (1978)
NR 9.0% 1.18 (0.71, 1.96) 0.99 (0.47, 2.08)
LEADER study [21,22] (2002) 23.4% 8.1% 1.23 (0.85, 1.77) 1.45 (0.62, 3.37)
E J Whitney [23] (2005) 21.5% 6.8% 0.90 (0.73, 1.12) -
FIELD study [24] (2005) 49.8% 19.6% 0.20 (0.01, 4.15) -
The ACCORD Study Group [25] (2010) 15.6% NR 1.06 (0.72, 1.56) 0.50 (0.15, 1.65)
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tified the trials by the degree of total cholesterol lowe-
ring, the RR in total cholesterol of less than 5% was 0.98
(95% CI, 0.67 to 1.45, P = 0.93), and the RR in total choles-
terol of 5% or more was 1.04 (95%, 0.92 to 1.18, P = 0.49).
Although we found inverse relation between total choles-
terol lowering and incidence of stroke, the results were
not affected by subgroup analysis. Similarly, there seemed
to be related between total cholesterol lowering and inci-
dence of fatal stroke, triglyceride lowering and incidence
of stroke, or fatal stroke. However, the effect of relation
was not a statistically significant, and the results were not
affected by subgroup analysis.
Subgroup analysis was performed for stroke, and fatal
stroke. We observed that gemfibrozil therapy was asso-
ciated with a statistical significant difference on the risk of
stroke (RR, 0.72, 95% CI, 0.53 to 0.98, P = 0.04, Table 3).
Furthermore, fibrate therapy might play a role in preven-
ting the event of fatal stroke (RR, 0.41, 95% CI, 0.17 to
1.00, P = 0.049, Table 3), when we included the trials with
Jadad score of 4. However, no other significant differences
were identified between the effect of fibrate therapy and
placebo based on other subset factors.
Egger’s test [16] was used to check potential publica-
tion bias. There was no evidence of publication bias for
the outcomes of fatal stroke (P value for Egger’s test,
0.34). However, we observed the evidence of publication
bias for stroke (P value for Egger’s test, 0.034). Subse-
quently, we used trim and fill methods [26] and found
that the conclusion was not changed after adjusting the
publication bias.
Discussion and conclusion
The results of our study indicated that fibrate therapy
has no effect on the incidence of stroke, and fatal stroke.Although VA-HIT study [10] has shown that fibrate
therapy can significantly reduce the risk of stroke, this
significant effect became attenuated or balanced by poo-
ling analysis with other trials.
The inverse relation between the total cholesterol low-
ering and incidence of stroke indicated that there is
causal relationship beween total cholesterol and the risk
of stroke. Previous meta-analysis [5] indicated that sta-
tins could effectively achieve target cholesterol goals and
reduce the risk of the event of stroke, which demon-
strated the relation between total cholesterol and the
incidence of stroke. Two previous large randomized
controlled trials, VA-HIT study [10] and BIP study [8],
suggest different conclusions. The VA-HIT study [10]
indicated that gemfibrozil therapy significantly reduced
the risk of stroke, which was consistent with our study.
However, BIP study [8] suggest that although bezafibrate
therapy increased the high density lipoprotein (HDL)
level and decreased triglyceride level, no effect was
observed on the incidence of stroke. Therefore, we car-
ried out a comprehensive systematic review and meta-
analysis to explain the possible effect of fibrate therapy
on the event of stroke. Our study was based on rando-
mized controlled trials and explored any possible correl-
ation between fibrates therapy and the outcomes of
stroke-related disease.
Our main findings are compared with the findings of
previous individual randomized controlled trials and
support the conclusion made by all included individual
trials except for VA-HIT study [10]. No significant diffe-
rence in the relative risk of stroke, or fatal stroke was
reported across a wide background of high-risk partici-
pants. In our study, participants with a history of stoke,
diabetes mellitus, myocardial infarction, coronary dis-
ease, lower extremity arterial disease, or high levels of
Zhou et al. BMC Neurology 2013, 13:1 Page 7 of 8
http://www.biomedcentral.com/1471-2377/13/1cholesterol, were included. However, an unimportant
heterogeneity was detected on the risk of stroke or fatal
stroke for the included trials. Another important factor
that may affect the results is the degree of total choles-
terol lowering, although stratified analysis based on the
changing of total cholesterol suggested it had no effect
on the risk of stroke. However, subgroup analysis indi-
cated that the RR of fibrate therapy on the risk of stroke
ranged from 0.93 to 1.15, and fatal stroke ranged from
0.69 to 0.81 when based on baseline total cholesterol
level. The reason for the suboptimal effect of fibrate
therapy could be that fewer trials reported the data of
stroke or fatal stroke events. Furthermore, although the
information about degree of total cholesterol lowering
was available, few trials reported some specific index,
such as the changing of LDL. As a result, we were un-
able to assess the relationship between the level of re-
duction in some specific index and the event of stroke,
or fatal stroke.
The relationship between serum total cholesterol le-
vels, LDL and stroke were described in previous indivi-
dual trials [27-30]. Epidemiological studies [31-33] also
indicated that low serum level of HDL had the risk of
cerebrovascular event. VA-HIT study [10] also supported
this conclusion. They illustrated that gemfibrozil in-
creased serum HDL levels by 6%, reduced triglyceride
levels by 31%, and the levels of serum LDL remained
same. This study indicated that gemfibrozil therapy could
effectively reduce the risk of stroke. However, in BIP study
[8] bezafibrate therapy increased HDL by 18%, reduced
TG by 21%, and LDL by 6.5%, BIP study [8] concluded
that fibrate therapy did not have an effect on the incidence
of stroke. We noted that the LDL values were higher in
BIP study [8] than in VA-HIT study [10], which might play
an important role to lessen or counter the effect of fibrate
therapy on the risk of stroke.
Although our study demonstrated no significant diffe-
rences between fibrate therapy and placebo in respect of
fatal stroke, when excluded WHO-COOP committee of
principal Investigators study [20] and LEADER study
[21,22] (two trials specifically included individuals with-
out previous with diabetes, cardiovascular disease or
stroke), a sensitivity analysis indicated that fibrates might
play a role in fatal stroke (RR, 0.49, 95% CI, 0.26 to 0.93,
without evidence of heterogeneity of effect). The reason
for this result could be that fibrate therapy resulted in
improved serum lipid profiles, which contributed an im-
portant role in the reduction of the incidence of recur-
rent event of stroke.
In our study, subgroup analysis illustrated that gemfi-
brozil therapy was associated with the reduction of risk
of stroke, which was decreased by 28% (RR, 0.72, 95% CI,
0.53 to 0.98). However, these conclusions might be un-
reliable because only a smaller number of trials [10,21]were included in such subsets. We just gave a relative re-
sult by comparing gemfibrozil therapy with placebo and
provided a synthetic and comprehensive review.
Our study also has several potential limitations. Firstly,
the result was based on published data, while individual
patient data and original data were not available, which
limited the capacity to fully explore the effects in sub-
group analysis. Secondly, although subgroup analysis
indicated that fibrate therapy significantly reduced the
risk of stroke, or fatal stroke for patients used gemfibro-
zil, or Jadad score of 4, these results might be variable
due to the small number of trials. Furthermore, different
baseline characteristic among participants might con-
tribute to the lack of difference revealed in our analysis.
In conclusion, our research suggested that fibrate the-
rapy had no significant effect on stroke, or fatal stroke.
Furthermore, our study could help personally appropri-
ate judgments about their own use of fibrate therapy,
and provide evidence to prevent the incidence of fatal
stroke in patients with cardiovascular disease or previous
stroke. Therefore, in future study, it is important to fo-
cus on patients with previous stroke or cardiovascular
disease for secondary prevention of the event of stroke
or recurrent stroke, and to combine other lipid-lowering
therapy, such as statins, to provide an optimal therapy to
prevent the incidence of stroke. We suggest that the
future trials could be improved by the following ways:
(i) promising interventions should be tested, including
dosage, duration of treatment or combination with influ-
encing factors, through which we might confirm the op-
timal time of treatment, the optimal dosage and the
optimal therapy. (ii) adverse event of trials should be
reported in details so that the side-effects of any treat-
ment could be evaluated in future trials.Additional file
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